Evidence map›Paper›PMID 38219334›Full record

Trial reportJournal of diabetes and its complications2024

Prevalence and predictors of erectile dysfunction among men in the diabetes prevention program outcomes study.

Yooni A Blair, Lindsay Doherty, Marinella Temprosa, Rodica Pop-Busui, Kishore M Gadde, Prachi Singh, Arthur H Owora, Hunter Wessells, Aruna V Sarma, Diabetes Prevention Program Research Group

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of diabetes and its complications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Yooni A BlairUniversity of Michigan Department of Urology, Ann Arbor, MI, United States of America. Electronic address: yooniy@med.umich.edu.
Lindsay DohertyBiostatistics Center, Milken Institute School of Public Health, The George Washington University, Rockville, MD, United States of America.
Marinella TemprosaBiostatistics Center, Milken Institute School of Public Health, The George Washington University, Rockville, MD, United States of America.
Rodica Pop-BusuiUniversity of Michigan Division of Metabolism, Endocrinology and Diabetes, Ann Arbor, MI, United States of America.
Kishore M GaddeUniversity of California Irvine, Department of Surgery, Orange, CA, United States of America.
Prachi SinghPennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA, United States of America.
Arthur H OworaIndiana University School of Public Health Department of Epidemiology and Biostatistics, Bloomington, IN, United States of America.
Hunter WessellsUniversity of Washington School of Medicine Department of Urology and Diabetes Research Center, Seattle, WA, United States of America.
Aruna V SarmaUniversity of Michigan Department of Urology, Ann Arbor, MI, United States of America.
Diabetes Prevention Program Research Group
University of Michigan–Ann Arbor · USMilken Institute · USIndiana University Bloomington · USPennington Biomedical Research Center · USUniversity of California, Irvine · USUniversity of Washington · US

Funding

PRIMARY PREVENTION TRIAL--DATA COORDINATING CENTERU01DK048489 · GEORGE WASHINGTON UNIVERSITY · 1994 to 2005
$23.7M
Post-DDP Follow-up StudyU01DK048413 · UNIVERSITY OF WASHINGTON · 1994 to 2005
$4.4M
TITLE OMITTEDU01DK048349 · YESHIVA UNIVERSITY · 1994 to 2005
$4.0M
PRIMARY PREVENTION TRIALU01DK048443 · UNIVERSITY OF SOUTHERN CALIFORNIA · 1994 to 2005
$4.0M
PRIMARY PREVENTION TRIAL (DPT-2)U01DK048397 · MASSACHUSETTS GENERAL HOSPITAL · 1994 to 2005
$3.8M
Post-DPP Follow-up StudyU01DK048485 · JOHNS HOPKINS UNIVERSITY · 1994 to 2005
$3.7M
NIDDM PRIMARY PREVENTION TRIALU01DK048412 · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 1994 to 2005
$3.6M
PRIMARY PREVENTION TRIAL (DPT-2)U01DK048339 · UNIVERSITY OF CALIFORNIA SAN DIEGO · 1994 to 2005
$3.6M
Post-DPP Follow-Up StudyU01DK048400 · WASHINGTON UNIVERSITY · 1994 to 2005
$3.6M
Post-DPP Follow-up StudyU01DK048437 · JOSLIN DIABETES CENTER · 1994 to 2005
$3.5M
NIDDM PRIMARY PREVENTION TRIAL (DPT 2)U01DK048404 · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · 1994 to 2005
$3.5M
Post-DPP Followup StudiesU01DK048411 · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · 1994 to 2005
$3.4M
NIDDK NIH HHS R01 DK116723NIDDK NIH HHS U01 DK048339NIDDK NIH HHS U01 DK048349NIDDK NIH HHS U01 DK048375NIDDK NIH HHS U01 DK048377NIDDK NIH HHS U01 DK048380NIDDK NIH HHS U01 DK048381NIDDK NIH HHS U01 DK048387NIDDK NIH HHS U01 DK048397NIDDK NIH HHS U01 DK048400NIDDK NIH HHS U01 DK048404NIDDK NIH HHS U01 DK048406NIDDK NIH HHS U01 DK048407NIDDK NIH HHS U01 DK048411NIDDK NIH HHS U01 DK048412NIDDK NIH HHS U01 DK048413NIDDK NIH HHS U01 DK048434NIDDK NIH HHS U01 DK048437NIDDK NIH HHS U01 DK048443NIDDK NIH HHS U01 DK048468NIDDK NIH HHS U01 DK048485NIDDK NIH HHS U01 DK048489NIDDK NIH HHS U01 DK048514NIDDK NIH HHS U24 DK076169NIDDK NIH HHS U24 DK115255
6 · The paper itself

Abstract

objectiveTo determine burden and identify correlates of erectile dysfunction (ED) among men with prediabetes (PreD) and type 2 diabetes (T2D) enrolled in the Diabetes Prevention Program (DPP) Outcomes Study (DPPOS). RESEARCH DESIGN AND

methodsThe 2017 DPPOS visit included administration of the International Index of Erectile Function. Of 648 male participants, 88 % (n = 568) completed the survey. Associations between sociodemographic, behavioral, clinical, and glycemic measures at time of ED assessment, and ED were examined using multivariable logistic regression models in men with PreD and T2D separately.

resultsOverall, 218 (38 %) men met ED criteria. Prevalence was similar in men with PreD (41 %) and T2D (37 %) (p = 0.4). In all men, age (p < 0.001) increased odds of ED. Among men with PreD, those assigned to intensive lifestyle intervention (ILS), but not metformin, had decreased odds of ED compared with the placebo group (OR = 0.35, 95 % CI = 0.13, 0.94). Non-Hispanic White race was associated with increased odds of ED compared with other races (OR = 4.3; 95 % CI = 1.92, 9.65). Among men with T2D, ED risk did not differ by DPP treatment assignment; however, individuals with metabolic syndrome defined by National Cholesterol Education Program criteria, had increased odds of ED (OR = 1.85, 95 % CI = 1.14, 3.01), as did individuals with depression (OR = 2.05; 95 % CI = 1.10, 3.79).

conclusionsED is prevalent in men with PreD and T2D. Our finding of reduced odds of ED in men randomized to ILS and with PreD suggests a potential opportunity for risk mitigation in the prediabetes interval. In men who have progressed to T2D, metabolic factors appear to be associated with ED.

Indexed as

Diabetes Mellitus, Type 2Erectile DysfunctionMetabolic SyndromePrediabetic StateFemaleHumansMalePrevalenceRisk FactorsDiabetesErectile dysfunctionPrediabetes

Identifiers

PMID38219334
PMCPMC10922921
OpenAlexW4390413892

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.